Activation of programmed (apoptotic) cell death for the treatment of prostate cancer.
Denmeade
S R
SR
Department of Oncology, and Urology, John Hopkins University School of Medicine, Baltimore, Maryland 21231, USA.
Isaacs
J T
JT
D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D015870:Gene Expression; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011355:Prodrugs; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy; D012717:Sesquiterpenes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D019284:Thapsigargin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D011355:Prodrugs; D012717:Sesquiterpenes; D019284:Thapsigargin